SCHEMBL6263784

SCHEMBL6263784

CNC(=O)c1cccc(N2CCNCC2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 1/20 0.60
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
ADRB1 P08588 3/20 0.54
HTR1A P08908 2/20 0.54
HTR7 P34969 2/20 0.54
HTR6 P50406 2/20 0.54
HTR3E A5X5Y0 1/20 0.54
HTR3B O95264 1/20 0.54
TP53 P04637 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
THRB P10828 1/20 0.54
CYP2C9 P11712 1/20 0.54
HTR2A P28223 1/20 0.54
HTR2C P28335 1/20 0.54
SLC6A4 P31645 1/20 0.54
CYP2C19 P33261 1/20 0.54
HTR2B P41595 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6413194 0.99 KAT6A (0.59) KAT6AMEN1KMT2AADRB1HTR1A
Phenylpiperazine SCHEMBL3894076 0.87 ALDH1A1 (0.63) KAT6AADRB1HTR1AHTR7HTR6
SCHEMBL13702428 0.86 MEN1 (0.66) MEN1KMT2ATP53ALDH1A1HSD17B10
SCHEMBL10154055 0.85 MEN1 (0.64) MEN1KMT2ATP53ALDH1A1HSD17B10
SCHEMBL13247636 0.84 PLOD2 (0.60) MEN1KMT2AHTR2AHTR2CALDH1A1
SCHEMBL3453744 0.83 ADRB1 (0.58) KAT6AMEN1KMT2AADRB1HTR1A
SCHEMBL4437239 0.82 KMO (0.68) MEN1KMT2AHTTALDH1A1MLYCD
SCHEMBL2876503 0.82 ADRB1 (0.59) KAT6AMEN1KMT2AADRB1HTR1A
Hydrochloric Acid SCHEMBL4713477 0.82 ADRB1 (0.57) KAT6AMEN1KMT2AADRB1HTR1A
SCHEMBL117252 0.81 ALDH1A1 (0.73) KAT6AMEN1KMT2AADRB1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050749-B1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI PHARMACEUTICAL CO LTD (JP) 2017-11-22 EP claimed
EP-1590329-A1 N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2005-11-02 EP disclosed
US-20050130989-A1 N-arylheteroaromatic products compositions containing them and use thereof AVENTIS PHARMA S. A. (FR) 2005-06-16 US disclosed
WO-2004078732-A1 N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130989-A1 N-arylheteroaromatic products compositions containing them and use thereof AHR, NQO1, ARNT KAT6A 2260/4885MEN1 1269/4885KMT2A 1284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.